Although cyclooxygenase (COX)-2 inhibitors (coxibs) are effective in controlling infl ammation, pain, and tumorigenesis, their use is limited by the recent revelation of increased adverse cardiovascular events. The mechanistic basis of this side effect is not well understood. We show that the metabolism of endocannabinoids by the endothelial cell COX-2 coupled to the prostacyclin (PGI 2 ) synthase (PGIS) activates the nuclear receptor peroxisomal proliferator -activated receptor (PPAR) ␦ , which negatively regulates the expression of tissue factor (TF), the primary initiator of blood coagulation. Coxibs suppress PPAR ␦ activity and induce TF expression in vascular endothelium and elevate circulating TF activity in vivo. Importantly, PPAR ␦ agonists suppress coxib-induced TF expression and decrease circulating TF activity. We provide evidence that COX-2 -dependent attenuation of TF expression is abrogated by coxibs, which may explain the prothrombotic side-effects for this class of drugs. Furthermore, PPAR ␦ agonists may be used therapeutically to suppress coxib-induced cardiovascular side effects.
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The cyclooxygenase (COX) pathway in vascular endothelium plays important roles in thrombosis, atherosclerosis, and vascular infl ammation ( 1 ) . Vascular endothelial cells (ECs) constitutively express COX-1 and -2 isoenzymes, leading to the generation of prostacyclin (PGI 2 ) and related molecules ( 2 ) . PGI 2 , a well-known inhibitor of platelet aggregation and a vasodilator, activates the IP-subtype of G protein -coupled receptors on the plasma membrane of platelets and vascular smooth muscle cells ( 1, 3 ) . In addition to activating cell surface receptors, PGI 2 and related molecules are potent activators of nuclear peroxisomal proliferator -activated receptor (PPAR) ␦ ( 4 -6 ). This mechanism was shown to be important for embryo implantation in mice ( 6 ) and in intestinal adenoma cell proliferation ( 7 ) and angiogenesis ( 8 ) .
The role of COX-2 in the regulation of EC phenotype is not well understood. In smallvessel endothelium, COX-2 is induced by growth factors and cytokines during infl ammation and angiogenesis ( 9 ) . In large-vessel ECs, COX-2 is constitutively expressed as a laminar shear -inducible gene ( 10 ) , which may be important for normal vascular homeostasis ( 11 ) . This issue has recently received considerable attention because administration of COX-2 -specifi c inhibitors (also known as the coxibs) leads to a small but substantial increase in prothrombotic side eff ects in humans, leading to the withdrawal of rofecoxib and valdecoxib from the market ( 12, 13 ) . The mechanistic basis of these side eff ects is not clearly understood, even though PGI 2 -dependent platelet eff ects and thromboxane-dependent vascular pathology have been implicated ( 14, 15 ) . In this study, we show that metabolism of endocannabinoids by the COX-2 pathway results in direct activation of the nuclear receptor PPAR ␦ . We further show that this pathway suppresses the expression of tissue factor (TF), which is a primary regulator of blood coagulation.
( Fig. 1 B ) . In addition, a dominant-negative PPAR ␦ construct ( 7 ) blocked the endocannabinoid-induced reporter activation (unpublished data).
Endocannabinoids are known to activate their G proteincoupled receptors CB1 and CB2 ( 18 ) . To determine whether the observed eff ects of endocannabinoids are mediated by CB receptors, we derived lung ECs from CB1/CB2 double knockout mice (Fig. S1 , available at http://www.jem.org/cgi/ content/full/jem.20070828/DC1) ( 19 ) . We found that 2-AG stimulated PPAR-dependent transcription in these cells lacking both CB1 and CB2 to an equivalent level of wild-type cells, suggesting that endocannabinoids are not acting via CB receptors ( Fig. 1 C ) . In contrast, when the PPAR ␦ -null lung ECs ( 20 ) were used in a similar assay, 2-AG failed to induce transcriptional activation, suggesting an absolute requirement for this transcription factor.
We next tested if COX-2 enzyme activity is required for 2-AG -induced PPAR ␦ transcription. Indeed, 2-AG -induced PPAR ␦ transcription in ECs was completely inhibited by NS-398, a COX-2 -selective inhibitor, but not by valeryl salicylate (VSA), a COX-1 -specifi c inhibitor ( Fig. 2 A ) . However, NS398 or VSA alone did not have any eff ect on PPAR ␦ − dependent transcription. 2-AG -induced PPAR transcription was absent in HCT116 colon cancer cells, which lack COX-2 expression but express COX-1 endogenously ( Fig. 2 B ) ( 21 ) . In contrast, direct activation of PPAR ␦ by cPGI, which is a stable PGI 2 analogue, induced transcription in HCT116 cells. More importantly, overexpression of COX-2 by adenoviralmediated transduction into HUVECs strongly induced PPAR ␦ transcription ( ‫ف‬ 25-fold), and this response was further potentiated ( ‫ف‬ 40-fold) by 2-AG ( Fig. 2 C ) . This increase was blocked by NS-398. Although COX-2 expression with the adenovirus induced high basal activity of the PPAR-responsive reporter, this is probably caused by effi cient transduction (Ͼ90% for HUVECs) and accumulation of COX-2 enzyme during the This description of the antithrombotic function of COX-2 may contribute to the mechanistic understanding of coxib-induced cardiovascular side eff ects seen in humans.
RESULTS AND DISCUSSION
The COX-2 isoenzyme has a larger active site pocket than COX-1 and therefore is capable of oxidizing many polyunsaturated fatty acids in addition to the common substrate arachidonic acid (AA) ( 16 ) . We tested if metabolism of various substrates of COX-2 would lead to intracellular activation of PPAR ␦ in ECs. Human umbilical vein ECs (HUVECs), which express COX-2 were transfected with a PPAR-responsive transcription reporter (pACO-Luc) ( 17 ) , incubated with various fatty acid substrates and transcriptional reporter (luciferase) activity was measured. As shown in Fig. 1 A , endocannabinoids, 2-arachidonyl glycerol (2-AG), noladin ether (NE), and anandamide (AEA) stimulated PPAR-dependent transcription. In contrast, the eff ect of AA was modest, and neither n-3 fatty acids (docosahexaenoic acid or eicosapentaenoic acid) nor non -COX-2 substrates (palmitate or oleate) induced PPARdependent transcription. The concentration of endocannabinoids that induced transcription is signifi cantly below the K m of 2-AG for COX-2, which is estimated to be ‫ف‬ 4 M ( 16 ). NE, which is a nonhydrolyzable ether analogue of 2-AG, is more potent, suggesting that hydrolytic pathways are involved in attenuating the 2-AG eff ect. These data provide evidence that endocannabinoid ligands, which are alternative substrates for COX-2 but not COX-1, are capable of activating the endogenous PPAR system in ECs.
The Gal4-UAS -based transcription reporter system was used to distinguish between the three PPAR isoforms ( 7 ), all of which are expressed in vascular ECs ( 17 ) . We observed that 2-AG primarily induces PPAR ␦ − dependent transcriptional activation in a dose-dependent manner, without significantly infl uencing PPAR ␣ -or PPAR ␥ -dependent transcription time course of the adenoviral expression. Similar arguments likely explain the incomplete inhibition by COX-2 inhibitor. Together, these results (overexpression, inhibitor sensitivity, and COX-2 -null cell data) establish that COX-2 activity is required for 2-AG -induced PPAR ␦ transcription.
Once fatty acid substrates are metabolized by COX-2 into endoperoxides, terminal synthases catalyze the formation of active prostanoids ( 1 ) . To determine which of the prostanoids are involved in PPAR ␦ transcription, we silenced the expression of genes encoding prostanoid synthases by siRNA in HUVECs and assayed the 2-AG -stimulated transcriptional response. As shown in Fig. 3 A , quantitative (q) RT-PCR analysis indicates that PGF 2 ␣ synthase (PGFS) and PGI 2 synthase (PGIS) mRNAs are highly expressed in HUVECs, although lower levels of cytosolic PGE 2 synthase mRNA are also expressed. The inducible microsomal PGE 2 synthase mRNA was not detected under basal conditions. This is consistent with our previous observation of abundant synthesis of 6-keto-PGF 1 ␣ (a stable breakdown product of PGI 2 ), PGF 2 ␣ , and PGE 2 in HUVECs ( 22 ) . PGIS or PGFS siRNA significantly suppressed the expression of PGIS or PGFS mRNAs in HUVECs, respectively ( Fig. 3 B ) . As shown in Fig. 3 C, 2-AG -induced PPAR ␦ transcription was inhibited by the PGIS, but not by the PGFS siRNA. These data suggest that conversion of 2-AG by COX-2 and PGIS into PGI 2 glycerol ester is critical for PPAR ␦ activation in ECs. Attempts to purify the PGI 2 glycerol ester or 6-keto-PGF 1 ␣ glycerol ester from EC extracts were not successful, which is presumably caused by high hydrolytic conversion of prostaglandin glycerol esters by cytosolic esterases ( 23 ) .
Because of the prothrombotic eff ects of coxibs observed in some patients ( 15, 24 ) , we analyzed the eff ect of modulating the COX-2 -PPAR ␦ pathway on TF expression in ECs. TF is the primary cellular initiator of blood coagulation, and its expression within the vasculature is associated with thrombosis ( 25 ) . We found that the COX-2 inhibitors celecoxib and NS398 induced TF mRNA expression, as determined by qRT-PCR ( Fig. 4 A ) . In contrast, activation of the COX-2 -PPAR ␦ pathway with either 2-AG or GW501516 decreased basal TF mRNA expression ( Fig. 4 A ) . Furthermore, 2-AG reduced celecoxib induction of TF mRNA expression ( Fig.  4 A ) . These data suggest that inhibition of COX-2 induces TF expression, whereas activation of the COX-2 -PPAR ␦ pathway suppresses TF expression. We isolated lung ECs from activation maintains the antithrombotic phenotype of the normal endothelium by suppressing the TF gene.
When HUVECs were treated with LPS, large induction of TF mRNA was seen; however, PPAR ␦ expression was not altered ( Fig. 4 B and not depicted). In fact, TF mRNA can be detected by Northern blot only after LPS treatment. COX-2 inhibitors NS398 and celecoxib enhanced LPS induction of TF mRNA expression ( Fig. 4 B ) . Similarly, celecoxib enhanced LPS induction of TF protein expression ( Fig. 4 C ) . In contrast, the PPAR ␦ agonist GW501516 and 2-AG both decreased LPS induction of TF mRNA expression ( Fig. 4 B ) . Concomitant regulation of TF polypeptide expression was observed as determined by an immunoblot assay ( Fig. 4 C ) . Rofecoxib, another COX-2 -selective inhibitor, also enhanced LPS induction of PPAR ␦ Ϫ/Ϫ mice and tested the expression of TF by qRT-PCR (Fig. S2 , available at http://www.jem.org/cgi/content/ full/jem.20070828/DC1). Unexpectedly, TF expression was lower than the wild-type counterparts. This phenomenon is analogous to the regulation of infl ammatory gene expression by PPAR ␦ in macrophages ( 26 ) . These authors showed that although PPAR ␦ agonists suppressed infl ammatory genes, PPAR ␦ -null macrophages had low expression of such genes. They further showed that release of the transcriptional repressor Bcl6 from the apo-PPAR ␦ is responsible for suppression of infl ammatory gene expression. We believe that an analogous phenomenon is operative in our PPAR ␦ -null ECs. Although molecular details of such mechanisms need to be further elucidated, our data suggest that COX-2 -dependent PPAR ␦ 
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by the EC COX-2 -PGIS system has important intracellular signaling fates. It is known that 2-AG is released upon cellular activation of platelets, monocytes, and ECs ( 30, 31 ) . Recent work shows that metabolism of 2-AG by the COX-2 pathway of the vascular endothelium occurs under physiological conditions and limits the activation of the CB receptors ( 32 ) . Although regulation of 2-AG production in human ECs need to be further examined, our data support the notion that 2-AG metabolism by the EC COX-2 pathway is biologically important. We speculate that the glycerol moiety of 2-AG may hinder its rapid secretion into the extracellular milieu, thereby facilitating the activation of intracellular receptors. Second, basal expression of COX-2 by EC, which is generally thought to be caused by physiological pulsatile shear forces ( 10 ), may be important for the tonic production of PPAR ␦ activators by the PGIS pathway. Our data supports the notion that 2-AG is an endogenous mediator that regulates the thrombotic phenotype of the vascular endothelium. Thus, antagonism of this pathway by COX-2 inhibitors would be anticipated to disrupt this endogenous regulatory mechanism (Fig. S3 , available at http://www.jem.org/cgi/content/full/ jem.20070828/DC1). In this context, recent work shows that 15-epi-lipoxin A 4 , which is an endogenous antiinfl ammatory mediator derived from EC COX-2 is also inhibited by the coxib treatment ( 33 ) , suggesting that multiple lipid mediators are perturbed by these drugs.
Third, we suggest that the PPAR ␦ pathway attenuates prothrombotic TF gene expression, and thus keeps the endothelium in an antithrombotic state. Recent work has highlighted the prothrombotic side eff ects of COX-2 inhibitors (coxibs) in humans ( 34 ) . Although the critical mechanisms involved remain to be elucidated, the importance of coxib inhibition of PGI 2 , the major vasoprotective prostanoid has been assumed to be the primary culprit ( 2, 11, 14 ) . Indeed, studies in mice show that perturbation of the PGI 2 receptor may control infl ammatory vascular pathology ( 11, 14 ) . Our study provides an alternative mechanism in understanding the prothrombotic complications of COX-2 inhibitors. Elevated TF expression in the luminal surface of blood vessel and/ or plasma may be one of the factors that contribute to the development of cardiovascular events in patients consuming COX-2 inhibitors ( 35 ) . Recent reports show that the use of coxibs and nonsteroidal antiinfl ammatory drugs are associated with increased mortality risk in patients with a history of cardiovascular disease ( 36, 37 ) . It is important to note that the side eff ects of coxibs only occur in a subset of patients, which is consistent with our in vitro data showing that coxibs induce TF expression modestly compared with LPS. Identifi cation of the at-risk population would off er obvious advantages, as coxibs and nonsteroidal antiinfl ammatory drugs are some of the most widely consumed antiinfl ammatory drugs and have shown activity as anticancer and antiangiogenic agents. This study has provided a potential mechanism by which COX-2 inhibitors may contribute to thrombotic complications, whereas a PPAR ␦ agonist would likely alleviate such adverse events.
TF protein expression in HUVECs in a dose-dependent manner, similar to celecoxib ( Fig. 4 D ) .
Next, we measured TF activity in HUVECs under similar experimental conditions. LPS induction of TF activity in HUVECs was enhanced by celecoxib in a dose-dependent manner ( Fig. 4 E ) . Preincubation of the cells with either GW501516 or 2-AG blocked this eff ect, and these agents decreased LPS induction of TF activity ( Fig. 4 E ) . In contrast to the results with HUVECs, celecoxib did not induce TF activity in peripheral blood mononuclear cells and did not enhance LPS induction of TF activity (unpublished data), which may be caused by the diff erences in the COX-2 -PGIS -PPAR ␦ pathway in these cells. These fi ndings indicate that the COX-2 -PPAR ␦ pathway serves to attenuate LPS-induced TF expression in the vascular endothelium. In addition, our data show that inhibition of this pathway by COX-2 inhibitors leads to the induction of TF expression.
Our results are in apparent contradiction with a recent study that showed that celecoxib, but not rofecoxib, inhibited the induction of TF expression in human aortic ECs stimulated with TNF-␣ in vitro ( 27 ) . The authors of that paper suggested that inhibition of JNK activity is critical for the modulation of TF expression. There could be several reasons for these discrepancies, e.g., diff erences in signaling by diff erent infl ammatory stimuli (LPS vs. TNF-␣ ) in cell-specifi c manner. However, in our work, we clearly show that the conversion of endocannabinoid (2-AG) by the COX-2 -PGIS pathway, followed by activation of PPAR ␦ , is involved in the regulation of TF mRNA and protein expression, as well as activity in HUVECs. In addition, as shown in the following paragraph, both COX-2 -and PPAR ␦ -dependent regulation of TF occurs in vivo as well.
We next determined whether the COX-2 -PPAR ␦ pathway regulates TF expression in ECs in vivo. Immunohistochemical analysis showed that LPS and/or celecoxib induced TF expression in ECs of blood vessels of lung and heart ( Fig.  5 A ) . Modulation of TF expression is seen in both microvessels and large vessels. GW501516 abolished this eff ect ( Fig. 5 A ) . The observation is consistent with other reports showing that TF is expressed in the endothelium in other diseases associated with thrombosis ( 28 ) .
Activated ECs release TF-positive microparticles into plasma ( 29 ) . Therefore, we obtained platelet poor plasma (PPP) from mice orally administered with either celecoxib or GW501516, followed by intraperitoneal LPS administration. We observed that treatment of mice with either LPS or celecoxib increased plasma TF activity (Fig. 5 B) . Treatment of mice with both LPS and celecoxib produced the highest levels of plasma TF, and such increase was abolished by pretreatment with the PPAR ␦ activator GW501516 (Fig. 5 B) . These data strongly suggest that the COX-2 pathway attenuates TF expression in vivo via the PPAR ␦ pathway. Inhibition of COX-2 activity by coxibs results in the induction of TF expression in the endothelium, which is further enhanced under infl ammatory conditions.
In summary, our results show the following novel fi ndings. First, metabolism of endocannabinoids, particularly 2-AG, (multiplicity of infection, 500), and the level of COX-2 expression was measured by either Western blot analysis or qRT-PCR. For transactivation assays after transfection, cells were transduced with either vector virus or adeno -COX-2 virus for 16 -24 h. Upon addition of COX-2 substrate, cells were harvested for luciferase activity as indicated above. Unless specifi ed, all compounds (2-AG, AA, GW501516, NS398, NE, AEA, and cPGI) were purchased from Cayman Chemical.
qRT-PCR. Total RNA was prepared using the RNA STAT-60 (Tel-test, Inc.) single-step isolation procedure according to the instructions provided by the manufacturer. 1 g total RNA was treated with DNase I before reverse transcription to ensure removal of all contaminating DNA. Using SYBR Green I DNA-binding dye technology (QIAGEN) reactions for each sample were done using an ABI 7900HT instrument (Applied Biosystems). All reactions underwent a fi nal dissociation curve determination to ensure a single PCR product at the correct melting temperature. Fluorescence data were exported and quantitated using a statistical model that corrects for PCR efficiency for each reaction. Results were expressed relative to the internal control gene glyceraldehyde-3-phosphate dehydrogenase for human or hypoxanthine phosphoribosyl-transferase I (HPRT) for mouse. Sequence of PCR primers were either obtained from the PrimerBank database (http://pga.mgh.harvard
MATERIALS AND METHODS
Cell culture, transfection, transduction, and luciferase assays. HUVECs (p3 -6; Glyco Tech Corporation or VEC TECHNOLOGIES, Inc.) were cultured as previously described ( 38 ) in complete growth medium (M199, 10% FBS, growth factor, and 1% antibiotic-antimicotic agent). Human colon carcinoma cells (HCT-116) were obtained from the American Type Culture Collection and were grown in Dulbecco ' s modifi ed Eagle ' s medium or RPMI with 10% FBS and 1% antibiotic-antimicotic agent.
For transient transfection, HUVECs (7.5 ϫ 10 4 cells) were seeded in 6-well plates, followed by transfection with a PPAR-responsive transcription reporter plasmid (pACO-gLUC), ␤ -galactosidase plasmid (p-␤ gal), and Lipofectamine 2000 in OPTI-MEM (Invitrogen) for 4 h, followed by the addition of 10% FBS containing media. After 16 -24 h, 0.01 -0.05% vehicle (DMSO) or indicated compounds were added and cells were harvested after 24 h in 1 ϫ luciferase lysis buff er. Relative light intensity from fi refl y luciferase activity was determined by using a luciferase kit (Promega) and a luminometer (Turner Designs). Relative luciferase activity was normalized to ␤ -galactosidase activity and protein content. All PPAR constructs were gifts from R. DuBois (Vanderbilt University Medical Center, Nashville, TN).
For adenoviral transduction, cells were infected with adenoviral vector containing human COX-2 cDNA or GFP cDNA as control for 48 h Figure 5 . Regulation of TF expression in vivo by celecoxib and a PPAR ␦ activator. C57BL/6J mice were treated with either vehicle (0.5% carboxymethyl cellulose), 25 mg/kg celecoxib, or 10 mg/kg GW501516 by gavage for 2 d. LPS ( E. coli serotype 0111; B4; Sigma-Aldrich) was injected i.p. (100 g/ mouse). After 4 -6 h, whole blood was collected from caudal vena cava into 10 ϫ acid citrate dextrose buffer to determine TF activity as previously described (see Materials and methods). Murine tissues were also harvested for immunohistochemistry. (A) Expression of TF protein in frozen tissue sections of lung and heart. Immunohistochemistry was conducted with monoclonal rat anti -mouse TF antibody and representative images are shown. The arrows and arrowheads indicate expression of TF protein in large vessels, as well as microvessels of both heart and lung. Bar, 20 m. (B) TF activity was measured in PPP as described in Materials and methods. TF concentration was interpolated as ⌬ A405-490 from a standard curve. n = 10 mice/group. *, P Ͻ 0.05; **, P Ͻ 0.01.
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Western blot analysis. HUVECs were treated with indicated compounds, as described in Northern blot analysis. Cells were washed with ice-cold phosphate-buff ered saline and harvested in radioimmunoprecipitation assay buff er (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 0.25% sodium deoxycholate, 1% Nonidet P-40, 1 mM EDTA, 1 mM EGTA, and 1 × protease inhibitor cocktail). Cells were lysed by three cycles of freeze (dry-ice/ethanol bath) and thaw (20 ° C), followed by centrifugation at 14,000 rpm for 20 min. Protein concentrations of supernatants were determined by BCA Protein Assay kit (Pierce Chemical Co.). Equal amounts of protein were separated on a 9% polyacrylamide gel and blotted to a nitrocellulose membrane for 1.5 h at 100 V. Immunoblot analysis was performed using 0.5 g/ml goat anti -human TF antibody (a gift from W. Ruf, The Scripps Research Institute, La Jolla, CA) and detected by horseradish peroxidase -conjugated rabbit anti -goat secondary antibody. Blots were developed with the Western blot development kit from GE Healthcare.
TF activity assays. Cell pellets from PBMCs or HUVECs were solubilized at 37 ° C for 15 min in 15 mM n-Octyl ␤ -D-glucopyranoside (EMD Biosciences). TF activity in cell lysates was measured using a one-stage clotting assay using human pooled plasma (American Diagnostica Inc.) ( 40 ) . Clotting was performed using a STart 4 clotting machine (Diagnostica Stago). Clotting times were converted to milliunits of TF activity using a standard curve established with purifi ed human brain TF. Protein concentrations were measured using a DC protein assay kit (Bio-Rad Laboratories), and TF activity was normalized to protein concentration. Data were expressed as fold induction versus control for each experiment.
A chromogenic assay (Actichrome TF; American Diagnostica, Inc.) was used to analyze TF activity. In brief, HUVECs were lysed by repeated freezethaw in buff er containing 50 mM Tris-HCl, 100 mM NaCl, 0.1% Triton X-100, pH 7.4. TF activity was measured in cell supernatant according to the manufacturer ' s instructions (American Diagnostica, Inc.). Cell extracts were mixed with human factor VII and human factor X. The reagents were incubated at 37 ° C for complex formation to convert human factor X to factor Xa, and the amount of Xa generated was measured by its ability to cleave a chromogenic substrate Spectrozyme Xa. Absorbance was read at 405 nm with a microplate reader (Spectra Max 340; Molecular Devices). TF concentration was determined by interpolation of a standard curve obtained from diff erent amounts of lipidated human TF standards. For TF activity measurement in mouse plasma, a mixture of 10% rat plasma/90% human plasma (SigmaAldrich) was added to the reaction mixture and ⌬ A405-490 was measured to calculate TF concentration.
In vivo studies. All animal experiments were approved by the University of Connecticut Institutional Animal Care and Use Committee. C57/BL/6J (4 -6 wk old; The Jackson Laboratory) mice were fed with either vehicle (0.5% carboxymethyl cellulose) or celecoxib (25 mg/kg body weight) or GW501516 (10 mg/kg body weight) by gavage for 2 d. 100 g LPS ( E. coli serotype 0111;B4; Sigma-Aldrich) was injected i.p. After 4 -6 h, mice were anaesthetized by Avertin and whole blood was collected from caudal vena cava for TF activity assay, followed by isolation of murine tissues for immunohistochemistry.
Immunohistochemistry. 5 -6-m-thick frozen sections of mouse tissue were dried overnight at room temperature then fi xed in acetone/ethanol (3:1 vol/vol) for 5 min at room temperature. All steps were performed in PBS buff er. Endogenous peroxidase was quenched with 3% hydrogen peroxide; nonspecifi c antibody binding was blocked with a 10% normal goat serum followed by blocking buff er. A rat anti -mouse TF antibody ( 41 ) (a gift from D. Kirchhofer, Genentech, Inc., San Francisco, CA) was biotinylated and used at 10 g/ml in blocking buff er, which was applied at room temperature for 1 h. Primary antibodies were detected with 2.5 g/ml rabbit anti -rat IgG, Vectastain ABC Elite (Vector Laboratories), and metal-enhanced DAB (Thermo Fischer Scientifi c). Sections were counterstained with Mayer ' s hematoxylin.
Isolation of blood and plasma. Whole blood was collected in acid-citrate dextrose (20 mM citric acid, 110 mM sodium citrate, and 5 mM dextrose).
.edu/primerbank/) or designed with Primer Express software (Applied Biosystems) for optimal product length, GC content, and melting temperature.
Northern blot analysis. Confl uent cultures of HUVEC cells were rendered quiescent for 48 h, followed by pretreatment with either vehicle, celecoxib, NS398, 2-AG, or GW501516 in fresh HUVEC medium for 30 min. 10 g/ml LPS ( Escherichia coli 0111:B4; Calbiochem) was added, and cells were treated for an additional 3 -6 h. Total RNA was isolated with the RNA STAT-60 reagent. 10 g of total RNA, quantitated spectrophotometrically, was electrophoresed through 1% agarose gel containing 4% (vol/vol) formaldehyde, and the integrity of the RNA was monitored by ethidium bromide staining. RNA was transferred onto Zeta-Probe membrane (Bio-Rad Laboratories), and was UV cross-linked by Stratalinker (Stratagene). A 641-bp human TF cDNA fragment was used to detect the TF mRNA. Specifi c cDNA probes were radioactively labeled by using [ 32 P]-␣ -dCTP (GE Healthcare) by a random primer labeling system (Roche). After cross-linking, the membranes were prehybridized in Church-Gilbert prehybridization buff er (7% SDS, 0.5 M phosphate buff er, 0.5% BSA, 40 mM EDTA, and 20% formamide) for 1 h. The membranes were hybridized with labeled probes for 18 h and washed following the Church-Gilbert protocol ( 38 ) . The membranes were stripped in stripping buff er (0.1 × SSC, 1% SDS, and 40 mM Tris-HCl, pH 7.6), rehybridized with diff erent probes, and visualized by PhosphorImager (Molecular Dynamics). The bands were quantifi ed using ImageQuant (Molecular Dynamics). The prehybridization, hybridization, and washing steps were all done at 65 ° C.
Small interfering RNA (siRNA) -mediated gene silencing. Transfection of siRNA oligonucleotide duplexes to block PGIS and PGFS expression was done using Oligofectamine reagent (Invitrogen) according to the manufacturer ' s instructions. The siRNAs used were human PGIS (sense AGGCCAGGAUGAAACUGACdTdT and antisense GUCAGUUUCAUCCUGGCCUdTdT). Oligonucleotides were synthesized by Dharmacon, deprotected, and duplexed. For, silencing of PGFS, SMARTpool PGF synthase siRNA was obtained from Dharmacon. HUVECs were transfected with either 100 nM PGIS or PGFS siRNA complexed with Oligofectamine reagent (Invitrogen) and, 24 h after transfection, gene expression was examined by qRT-PCR analysis. E-cadherin (siRNA against epithelial cadherin was used as control).
Isolation of mouse lung ECs. Lungs isolated from 21-d-old (C57/B6/129 mixed) mice were washed several times in Hanks ' balanced salt solution and digested with 2 mg/ml collagenase A (Roche) in M199 medium, with occasional mixing at 37 ° C. After treatment with 1 g/ l DNaseI, the suspension was passed through a cell strainer (40 m nylon; BD Biosciences) to remove any undigested remains. After a brief spin, the supernatant was treated with rat anti -mouse CD31 monoclonal antibody (BD Biosciences) for 20 min at 4 ° C. The cell suspension was spun and washed twice in plain M199 medium. Resuspension of the pellet in M199 medium was followed by treatment with magnetic Dynabeads sheep anti -rat IgG (Dynal Biotech) at 4 ° C in a rotator. Bead-bound cells were washed and separated from the unbound cells by a magnetic bar. Cells were plated in fi bronectin-coated tissue culture dish in M199, 10% FBS, growth factor, and antibiotic-antimicotic agents. After 24 h, the cells were immortalized with a retrovirus that expresses polyoma middle-T-antigen ( 39 ).
Immunofl uorescence. Cells grown on glass coverslips for 48 h were washed with PBS, fi xed in 3.7% paraformaldehyde solution for 15 min at room temperature, and permeabilized with 0.2% Triton X-100 in PBS for 5 min at room temperature. After rinsing with PBS, cells were incubated with a goat polyclonal anti -VE-cadherin antibody (1:200; Santa Cruz Biotechnologies) for 1 h at room temperature. After washing with PBS few times, cells were further incubated with Alexa Fluor 488 donkey anti -goat IgG (1:1,000; Invitrogen) in 5% nonfat dry milk in PBS for 30 min at room temperature. After washing with PBS, cells were analyzed by a Zeiss Axiovert fl uorescence microscope.
Statistical analysis. All data were expressed as the mean Ϯ the SEM. Statistical diff erences between two groups were analyzed using Student ' s t test unless specifi ed. P Ͻ 0.05 was considered signifi cant. All experiments represent the mean of three or more independent experiments. For in vivo experiments, a signifi cance outlier detection program using Grubb ' s test was performed for each experimental group.
Online supplemental material. Fig. S1 shows the characterization of mouse lung endothelial cells. Fig. S2 shows TF expression in PPAR ␦ ϩ/ϩ and PPAR ␦ Ϫ/Ϫ mouse lung endothelial cells. Fig. S3 shows a schematic of COX-2 regulation of TF expression in endothelial cells. Fig. S4 shows structures of 2-AG, NE, AA, and AEA. The online version of this article is available at http://www.jem.org/cgi/content/full/jem.20070828/DC1.
